Lab
Phase2 Labs, LLC
Phase2 Labs, LLC was paid $192K by Medicaid between Feb 2023 and Dec 2024, across 55 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 34% of everything it billed.
33Billing provider infoPHASE2 LABS, LLC
NASHVILLE, TN 37217
NASHVILLE, TN 37217
33aNPI1760077606assigned 03/03/2021
33bProvider typeClinical Medical Laboratory
28Total paid$192K
24GClaims20,317
24DCodes billed55
24AFirst – last monthFeb 2023 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Tennessee
Rank by total paid#33 of 70
Median peer was paid$141K
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 5,776 | $45K | |
| 2024incomplete | 14,541 | $147K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 34% | 1,193 | 922 | $65K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 14% | 1,402 | 1,004 | $27K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 8.6% | 771 | 657 | $17K |
| 87481 | 6.6% | 745 | 610 | $13K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.7% | 553 | 448 | $9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.5% | 997 | 790 | $5K |
| 87500 | 2.3% | 754 | 612 | $4K | |
| 87641 | 2.3% | 710 | 580 | $4K | |
| 87653 | 2.0% | 763 | 611 | $4K | |
| 87563 | 1.8% | 651 | 540 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.6% | 249 | 198 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.6% | 249 | 198 | $3K |
43 more codes
| 87640 | 1.3% | 777 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.2% | 180 | $2K |
| 80361 | <1% | 404 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 272 | $2K |
| 80354 | <1% | 403 | $1K | |
| 80372 | <1% | 396 | $1K | |
| 80365 | <1% | 403 | $1K | |
| 80373 | <1% | 397 | $1K | |
| 80364 | <1% | 395 | $1K | |
| 80347 | <1% | 367 | $1K | |
| 80358 | <1% | 396 | $1K | |
| 80348 | <1% | 390 | $1K | |
| 80323 | <1% | 363 | $1K | |
| 80333 | <1% | 360 | $977.91 | |
| 80338 | <1% | 360 | $957.44 | |
| 80370 | <1% | 381 | $956.77 | |
| 80335 | <1% | 354 | $915.03 | |
| 87631 | <1% | 62 | $914.26 | |
| 80345 | <1% | 362 | $914.12 | |
| 80349 | <1% | 394 | $803.02 | |
| 80355 | <1% | 388 | $792.79 | |
| 80366 | <1% | 386 | $688.18 | |
| 87581 | <1% | 114 | $664.87 | |
| 80324 | <1% | 371 | $632.35 | |
| 87486 | <1% | 114 | $608.73 | |
| 80360 | <1% | 370 | $576.36 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 74 | $566.87 |
| 80359 | <1% | 364 | $565.47 | |
| 80368 | <1% | 366 | $554.06 | |
| 83992 | <1% | 364 | $462.19 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 185 | $394.39 |
| 87077 | <1% | 140 | $279.73 | |
| 87541 | <1% | 17 | $247.29 | |
| 82607 | <1% | 53 | $202.48 | |
| 80061 | Lipid panel | <1% | 74 | $197.19 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 96 | $149.81 |
| 80053 | Comprehensive metabolic panel | <1% | 90 | $64.52 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 75 | $60.38 |
| 81001 | <1% | 40 | $38.39 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 81 | $36.96 |
| 36415 | Collection of venous blood by venipuncture | <1% | 22 | $17.40 |
| 87632 | 0% | 17 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 63 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAYDEN, TYLER (DIRECTOR OF OPERATIONS)